Europe Therapeutic Vaccines Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The Europe therapeutic vaccines market size is expected to reach US$ 14,76,492.99 thousand by 2031 from US$ 6,39,242.94 thousand in 2024. The market is estimated to record a CAGR of 12.7% from 2024–2031.

Executive Summary and Europe Therapeutic Vaccines Market Analysis:

Europe therapeutic vaccines market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The market growth is attributed to advanced healthcare infrastructure and increasing investments in research and development. Europe is home to leading pharmaceutical companies and biotech firms focused on innovative vaccine therapies for a range of diseases, including cancer. The increasing prevalence of chronic diseases and the growing awareness of personalized medicine further fuel the demand for therapeutic vaccines in Europe. The market is expected to continue growing, with advancements in immunotherapies and the potential for new vaccine technologies offering promising opportunities for expansion across Europe. 

Europe Therapeutic Vaccines Market Strategic Insights

Get more information on this report Request Free Sample PDF

Europe Therapeutic Vaccines Market Segmentation Analysis

Key segments that contributed to the derivation of the therapeutic vaccines market analysis are product, technology, and end user.

• By product, the therapeutic vaccines market is segmented into cancer vaccines, infectious disease vaccines, and others. The cancer vaccines held the largest share of the market in 2024.
• By technology, the therapeutic vaccines market is segmented into allogenic vaccine and autologous. The allogenic held the largest share of the market in 2024.
• By end user, the therapeutic vaccines market is segmented into hospital, clinics, and others. The hospital held the largest share of the market in 2024.

Europe Therapeutic Vaccines Market Outlook

Therapeutic vaccines stimulate the immune system to aid the treatment of cancer, autoimmune disorders, and chronic infections. The growing investments and funding for vaccine development drive the expansion of the therapeutic vaccines market, fostering innovation and accelerating the development of novel treatments for chronic diseases. Over the past decade, global investments in vaccine research and development (R&D) have increased significantly, with governments, private institutions, and pharmaceutical companies recognizing the importance of therapeutic vaccines in addressing unmet medical needs. They are investing in new technologies, platforms, and approaches to develop innovative therapeutic vaccines, particularly for diseases that have limited therapeutic options, such as certain cancer types and viral infections. For instance, in 2021, GlaxoSmithKline (GSK) allocated US$ 6.46 billion (£5.3 billion) toward R&D, extending a robust budget to establish a pipeline featuring 43 medicines and 21 vaccines; with nearly 50% of these drugs target infectious diseases. This pipeline includes ongoing vaccine development programs aimed at providing protection against COVID-19 and influenza, as well as innovative therapeutic vaccine approaches for chronic hepatitis B virus infections, building upon decades of achievement in prophylactic vaccines. Initiatives entailed by its pipeline leverage diverse technologies to proactively combat diseases across all age demographics.

Additionally, investments are flowing into oncology-focused vaccines, with companies applying their mRNA technologies to create therapeutic vaccines for various cancers. eTheRNA Immunotherapies, a clinical-stage organization, was awarded a TIGER grant of US$ 7.1 million (€6.9 million) by the European Commission as part of its Horizon 2020 research and innovation program. This funding is designated for the development of an innovative mRNA cancer vaccine aimed at treating recurrent or metastatic HPV16+ cancers. Similarly, In August 2022, researchers at Queen's University Belfast in Northern Ireland secured funding from Breast Cancer Now to explore new treatments inspired by COVID-19 vaccine innovation. The research team from the School of Pharmacy received a grant of US$ 278,168 (GBP 228,900) to address the role of the p53 protein, which is present in ~90% of triple-negative breast cancer tumors. This team is engaged in developing new treatments for an aggressive form of breast cancer. Their efforts are focused on developing an mRNA vaccine that will enhance the immune system's ability to identify, target, and destroy cancer cells exhibiting p53 mutations. Such funding initiatives are fueling innovations in therapeutic vaccines, leading to the development of more effective and targeted treatments for a variety of diseases, including cancers and chronic infections. These investments are also directed toward exploring unconventional approaches, such as cancer immunotherapy vaccines, which could revolutionize treatment options.

Thus, the increasing investments and funding for vaccine development contribute significantly to the growth of the therapeutic vaccines market.

Europe Therapeutic Vaccines Market Country Insights

Based on country, the Europe therapeutic vaccines market comprises the Germany, Italy, France, the UK, Spain, and the Rest of Europe. Germany held the largest share in 2024.

Germany has one of the most advanced healthcare systems in the world, with its well-established pharmaceutical and biotechnology industries that provide a foundation for the development and commercialization of therapeutic vaccines. There is a large patient pool and a high demand for quality healthcare in the country. The German market, supported by its robust healthcare infrastructure and extensive research and development capabilities, is a significant player in the therapeutic vaccine sector. One of the growth factors in the therapeutic vaccines market in Germany is the increasing prevalence of chronic and infectious diseases. As per the data published in “Hepatitis B: Annual Epidemiological Report for 2022,” in the country, the number of reported hepatitis B cases and rates per 100,000 population stood at 16,674 in 2022.

Germany’s strong research ecosystem and collaborative efforts between academic institutions, hospitals, and biotech companies are accelerating the development of new therapeutic vaccines. For example, The German Cancer Research Center (DKFZ) conducts pioneering research in cancer immunotherapy and vaccine development, contributing to the country’s role as a hub for medical innovation. In August 2024, researchers at the DKFZ introduced a novel vaccine aimed at boosting HPV vaccination rates, targeting cancer-causing human papillomaviruses (HPV). 

Europe Therapeutic Vaccines Market Report Highlights

Europe Therapeutic Vaccines Market Company Profiles

Some of the key players operating in the market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Therapeutic Vaccines Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis, and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

Europe Therapeutic Vaccines Market Country and Regional Insights